LIGAND PHARMACEUTICALS INCORPORATED Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
LIGAND PHARMACEUTICALS INCORPORATED (LGND) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $11.57 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.57M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $10.73M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.89M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.16M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $11.57M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $10.73M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $11.89M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $11.16M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $9.74M 10-K · filed 2023-02-28 | $11.37M 10-K · filed 2022-02-28 |
| 2020-12-31 | $11.99M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $9.54M 10-K · filed 2021-02-24 |